A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).

Autor: McGowan IM; Orion Biotechnology, Ottawa, Canada.; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA., Chawki S; INSERM, Paris, France.; Department of Virology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, France., Hendrix CW; Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland, USA., Anton PA; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA., Marzinke MA; Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland, USA., Brand RM; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA., Engstrom JC; Orion Biotechnology, Ottawa, Canada., Rohan LC; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA., Abebe KZ; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Richardson-Harman N; Alpha StatConsult LLC, Damascus, Maryland, USA., Siegel A; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA., Reinhart A; ViiV Healthcare, Uxbridge, United Kingdom., Steytler J; International Partnership for Microbicides, Silver Spring, Maryland, USA., Stall R; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Spiegel H; Kelly Government Solutions, Department of Health and Human Services, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA., Chen B; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA., Achilles SL; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA., Jacobson CE; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA., Khanukova E; Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland, USA., Cranston RD; Department of Medicine, University of Barcelona, Barcelona, Spain.

Publikováno v: AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2022 Apr; Vol. 38 (4), pp. 269-278. Date of Electronic Publication: 2021 Sep 14.

A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).

Autor: Mcgowan I; University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Cranston RD; University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America., Duffill K; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Siegel A; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Engstrom JC; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Nikiforov A; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Jacobson C; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Rehman KK; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Elliott J; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, United States of America., Khanukhova E; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, United States of America., Abebe K; University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America., Mauck C; CONRAD, Arlington, Virginia, United States of America., Spiegel HM; HJF-DAIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America., Dezzutti CS; University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Rohan LC; University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America; Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America., Marzinke MA; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America., Hiruy H; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America., Hendrix CW; Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America., Richardson-Harman N; Alpha StatConsult LLC, Damascus, Maryland, United States of America., Anton PA; David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, United States of America.

Publikováno v: PloS one [PLoS One] 2015 May 05; Vol. 10 (5), pp. e0125363. Date of Electronic Publication: 2015 May 05 (Print Publication: 2015).